These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3905084)

  • 1. Aluminium toxicity in chronic renal insufficiency.
    Savory J; Bertholf RL; Wills MR
    Clin Endocrinol Metab; 1985 Aug; 14(3):681-702. PubMed ID: 3905084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in aluminum toxicology.
    Monteagudo FS; Cassidy MJ; Folb PI
    Med Toxicol Adverse Drug Exp; 1989; 4(1):1-16. PubMed ID: 2651849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium.
    Ward MK; Feest TG; Ellis HA; Parkinson IS; Kerr DN
    Lancet; 1978 Apr; 1(8069):841-5. PubMed ID: 76795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trace metals and degenerative diseases of the skeleton.
    Savory J; Bertholf RL; Wills MR
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 7():282-8. PubMed ID: 3776576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early effects of aluminium deposition and dialysis on bone in chronic renal failure: a cross-sectional bone-histomorphometric study.
    Dahl E; Nordal KP; Halse J; Flatmark A
    Nephrol Dial Transplant; 1990; 5(6):449-56. PubMed ID: 2122323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)].
    Buge A; Poisson M; Masson S; Bleibel JM; Lafforgue B; Raymond P; Jaudon MC
    Nouv Presse Med; 1978 Jun; 7(23):2053-9. PubMed ID: 673773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localisation of aluminium by histochemical and electron probe x-ray microanalytical techniques in bone tissue of cases of renal osteodystrophy.
    Smith PS; McClure J
    J Clin Pathol; 1982 Nov; 35(11):1283-93. PubMed ID: 7142436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronological study of signs of myoclonic encephalopathy in hemodialysis patients (author's transl)].
    Vecchierini-Blineau MF; Thebaud HE; Dupouet L; Brochard D; Coville P; Feve JR; Guiheneuc P
    Sem Hop; 1981 Nov 18-25; 57(43-44):1823-30. PubMed ID: 6274030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminium studies in dialysis encephalopathy.
    Elliott HL; Macdougall AI
    Proc Eur Dial Transplant Assoc; 1978; 15():157-63. PubMed ID: 740662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma aluminium: a redundant test for patients on dialysis?
    Gault PM; Allen KR; Newton KE
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload and bone disease in chronic dialysis patients.
    Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME
    Nephrol Dial Transplant; 1990; 5(9):781-7. PubMed ID: 2129351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response relationships in aluminium toxicity in humans.
    Coulson JM; Hughes BW
    Clin Toxicol (Phila); 2022 Apr; 60(4):415-428. PubMed ID: 35179097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dialysate aluminium concentration and renal bone disease.
    Walker GS; Aaron JE; Peacock M; Robinson PJ; Davison AM
    Kidney Int; 1982 Feb; 21(2):411-5. PubMed ID: 7070002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
    Allain P; Chaleil D; Mauras Y; Beaudeau G; Varin MC; Poignet JL; Ciancioni C; Ang KS; Cam G; Simon P
    Clin Chim Acta; 1987 Dec; 170(2-3):331-8. PubMed ID: 3436066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.